ALLEVIATE – HF Clinical Trial

Cardiology Associates Research, LLC just completed enrollment in the ALLEVIATE-HF study. The ALLEVIATE-HF study utilized the Medtronic LINQ device, which is an implantable loop recorder, to monitor fluid levels in patients with heart failure with a reduced or preserved ejection fraction. After implantation of the device, a Medtronic field representative with the study team would upload algorithms using LINQ sensors to evaluate and treat heart failure. Medtronic supplied the patient with in-home biometric monitoring equipment to evaluate daily weights and blood pressure. Medtronic nurses that specialize in heart failure are able to monitor the patients remotely. The Principal Investigator or Sub-Investigator will write a prescription for “as-needed” intervention that these nurses initiate in the event of volume (fluid) overload. The premise of the study is to observe patients remotely through the LINQ device and initiate a “as-needed” intervention to hopefully decrease the number of ER visits and hospitalizations for patients with heart failure.

Cardiology Associates Research, LLC enrolled the first patient in the US on September 3, 2020. Our site enrolled 41 patients with the last patient enrollment on August 27, 2024. Out of 54 sites in the US, our site was #6 in the nation. Our site managed to continue enrollment even through the COVID crisis. Due to the strong support of our PI and Sub-I’s, we were able to enroll and provide our patients with an opportunity to better treat and live with heart failure.